Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Beyond Meat

Carvana

GameStop

Nikola

Rivian Automotive

Terawulf

As a critical mass of risk-hungry traders now believe “the coast is clear,” now may be the perfect time to consider which meme stocks to short. What do I mean by “the coast is clear?

Smart Shorts: 7 Meme Stocks to Bet Against in 2024

ChargePoint Holdings

Lucid Group

There was a time when investors used to avoid heavily shorted stocks. Building-up of short interest indicates a bearish view of the stock, translating into a sustained correction.

3 Heavily Shorted Stocks That Still Won't See a Squeeze

Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?

Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?

Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

During the meme stocks rally of 2021, it seemed that all potential meme stocks skyrocketed. The speculative activity peaked, and short-squeeze rallies delivered multi-bagger returns in weeks.

3 Meme Stocks That Could Fade Away in 2024

Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older.

Health Canada authorizes Novavax's updated COVID shot for Omicron

Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

Novavax's prospects in the COVID-19 vaccine market look uncertain. The rest of the company's pipeline doesn't look inspiring.

Is Novavax Stock a Buy Now?

C3.ai

SunPower

Short squeezes, which are characterized by sudden and substantial surges in asset prices, have become prominent and debated phenomena on Wall Street in recent years. A short squeeze occurs when a high number of traders who shorted a given instrument are compelled to close their positions, ultimately pushing the asset's price higher.

3 Short-Squeeze Stocks That Could Take Off Before Year-End

Moderna

Pfizer

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday.

WHO authorizes emergency use of Novavax's updated COVID vaccine

Novavax Inc.'s stock NVAX soared 4.6% early Tuesday, after the company said its protein-based COVID-19 vaccine had been granted emergency-use listing by the World Health Organization. The move means that all 194 of the agency's member states can use the Novavax vaccine for individuals aged 12 and older.

Novavax's stock pops after WHO grants its COVID-19 vaccine emergency-use listing

GAITHERSBURG, Md. , Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?

Is Novavax Stock A Sell After New Covid Shot Fails To Bolster Its Outlook?

New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans John Trizzino appointed to new Chief Operating Officer role Mark Casey to join as Chief Legal Officer and Corporate Secretary GAITHERSBURG, Md. , Nov. 17, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

Novavax, Inc. (NASDAQ:NVAX ) Jefferies London Healthcare Conference November 15, 2023 4:00 AM ET Company Participants Roger Song - Jefferies Conference Call Participants John Jacob - President & CEO Filip Dubovsky - President of Research and Development Jim Kelly - EVP & CFO Roger Song All right. Good morning, everyone.

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference (Transcript)

Upstart Holdings

Novavax raised going concern issues this year, and its problems aren't going away. Beyond Meat's sales are declining and its margins are awful.

Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?

Novavax has struggled since its coronavirus vaccine reached the market after the vaccines of rivals. But the company has launched a cost-cutting plan and aims to bring a new game-changing vaccine to market in a few years.

Where Will Novavax Be in 3 Years?

Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.

Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View

GAITHERSBURG, Md. , Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.

Novavax to Participate in Jefferies London Healthcare Conference

Novavax, Inc. (NASDAQ:NVAX ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President & CEO John Trizzino - Chief Commercial Officer & Chief Business Officer Filip Dubovsky - President of Research & Development James Kelly - CFO Conference Call Participants Roger Song - Jefferies Eric Joseph - JP Morgan Brendan Smith - TD Cowen Mayank Mamtani - B. Riley Alec Stranahan - Bank of America Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q3 2023 Earnings Call Transcript

Novavax Inc. shares NVAX, -4.09% moved slightly higher premarket on Thursday after the company reported a narrower-than-expected third quarter loss but trimmed its 2023 sales guidance.

Novavax shares rise as third quarter results top expectations

Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option Secured broad access to Novavax's COVID-19 vaccine in the U.S. R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch Anticipate Phase 3 COVID-19-Influenza Combination vaccine trial to commence in 2024, with potential for accelerated approval and launch in 2026 Expect to deliver total revenue at low end of guidance range for season, when accounting for some revenue shifting into first quarter 2024 Prepared to initiate additional cost reduction program, targeting over $300 million in 2024 to align company scope and structure with future COVID-19 market opportunity Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights

COVID-19 vaccine maker Novavax on Thursday beat Wall Street estimates for third-quarter revenue, boosted by U.S. government grants to help cover the expense of clinical trials, sending its shares up nearly 4% in premarket trade.

News for Novavax Stock (NVAX)